BridgeBio Pharma stock rating reiterated at Buy by TD Cowen

TD Cowen reiterated a Buy rating on BridgeBio Pharma with a $95 price target versus the $70.84 share price, implying meaningful upside. The firm said the Pfizer tafamidis settlement removes a key overhang and gives BridgeBio roughly 7.5 to 8 years to build Attruby before tafamidis generics materially pressure growth. Other analysts also remain positive, with price targets of $100 to $111, while BridgeBio continues to expand awareness for ATTR-CM through a national campaign.

Analysis

The cleanest read is that the litigation resolution removes a binary discount from BBIO, but the market is still underpricing how long the company can compound before tafamidis competition becomes a real volume issue. That creates a multi-year runway for execution, which matters more than near-term consensus upside because this stock has likely been trading on a compressed probability-weighted model that embedded patent-risk overhang and slower launch adoption.

Second-order, the biggest beneficiary is not just BBIO but the ATTR treatment ecosystem: more physician attention, more diagnostic capture, and broader payer familiarity can expand the addressable pool for every product in the category. The company’s awareness push is strategically important because market expansion in rare disease is often driven by diagnosis rate, not just market share; that means the growth lever is less about stealing patients from tafamidis and more about converting an underdiagnosed funnel. That makes the next 2-4 quarters a data-validation period on script acceleration rather than a legal headline trade.

The main risk is that investors extrapolate “clear runway” too aggressively and ignore launch kinetics. If Attruby uptake decelerates after the initial awareness surge, the market will reprice BBIO from a de-risked growth story back to a product-execution story, and that can happen within 1-2 earnings prints. PFE is less of a direct loser than a sentiment reference point; the broader lesson is that the competitive moat in this market is increasingly commercial and diagnostic, not purely patent-based.

Consensus appears to be treating this as a durable multiple expansion catalyst, but the move may be overdone if the stock is already pricing a smooth ramp and a benign competitive backdrop. The better trade is to own BBIO through launch inflection while hedging the event-risk around uptake, payer behavior, and any evidence that generic entry changes prescribing more quickly than expected.

Key Decisions for Investors

• Long BBIO on a 3-6 month horizon; add on post-news consolidation rather than strength. Risk/reward favors a rerating if Attruby script growth validates, with downside limited by the removal of the patent overhang.
• Buy BBIO calls 6-12 months out to express upside with defined risk; target a structure that benefits from multiple expansion into the next two earnings cycles.
• Pair trade: long BBIO / short a basket of slower-growth biotech names with similar market caps but no near-term launch catalyst. This isolates the de-risking and launch-growth premium.
• If owning BBIO common, hedge into earnings with short-dated puts or collars. The key risk is not litigation reversal but a disappointment on launch slope over the next 1-2 quarters.
• Monitor PFE only as a sentiment barometer, not a direct trade; if broader anti-patent/anti-pharma sentiment fades, BBIO’s multiple can expand further even without incremental news.